TBC-2576

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameTBC-2576
Drug Alias Nameendothelin antagonist (Texas Biotechnology)TBC-2576
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor antagonists
TargetsVascular endothelial growth factor receptor
Therapy Area/IndicationsGlaucomaDiabetic NeuropathiesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEncysive Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEncysive Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsGlaucomaDiabetic NeuropathiesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A